Aligos Therapeutics has been granted a patent for compounds of Formula (I) and their pharmaceutically acceptable salts, along with methods of synthesis and treatment of diseases. The patent claim includes the specific structure of the compound. GlobalData’s report on Aligos Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Aligos Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Aligos Therapeutics's grant share as of May 2024 was 4%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11957683B2) discloses a compound of Formula (I) or a pharmaceutically acceptable salt thereof, designed for the treatment of hepatitis B and hepatitis D. The compound, as described in the claims, includes specific structural features such as substituted aryl groups and alkyl chains, aimed at enhancing its therapeutic efficacy in combating these viral infections. The patent also covers pharmaceutical compositions containing the compound and methods for treating hepatitis B and hepatitis D by administering the disclosed compound to subjects in need of such treatment.
Moreover, the patent outlines a method for treating hepatitis B and hepatitis D by administering the compound along with additional agents like interferons, nucleoside analogs, and immunomodulators. This combination therapy approach aims to provide a comprehensive treatment strategy for effectively managing these viral infections in affected subjects. The patent's focus on specific structural characteristics of the compound and its application in treating hepatitis B and hepatitis D underscores the innovative nature of the disclosed invention in the field of antiviral therapeutics.
To know more about GlobalData’s detailed insights on Aligos Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
